This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
MDT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDT vs. LMAT: Which Stock Is the Better Value Option?
Company News for Feb 21, 2024
by Zacks Equity Research
Companies in The News Are: WMT, MDT, NFLX, MPC
Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
Medtronic (MDT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended January 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 1.73%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $83.68, marking a +0.11% move from the previous day.
What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q3 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Medtronic (MDT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended January 2024.
QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.08% and 6.97%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $86.18, denoting a -1.12% change from the preceding trading day.
Medtronic (MDT) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $86.75, signifying a -1% move from its prior day's close.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $86.97, representing a -0.54% change from its previous close.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $84.72, signifying a -1.88% move from its prior day's close.
Medtronic (MDT) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $86.29, signifying a +0.28% move from its prior day's close.
Medtronic (MDT) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $87.09, signifying a +0.01% move from its prior day's close.
Medtronic's (MDT) Percept RC DBS System Secures FDA Approval
by Zacks Equity Research
Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.
Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync
by Zacks Equity Research
Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.
Wearable Technology Market Gains Ground, 3 Stocks in Focus
by Moumi Mondal
In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.
Casey's General Stores and Westlake have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Casey's General Stores and Westlake are part of the Zacks Bull and Bear of the Day article.